Author: Yu, Miao; Terhorst-Molawi, Dorothea; Altrichter, Sabine; Hawro, Tomasz; Chen, Yu-Di; Liu, Bo; Song, Xiao-Ting; Zhao, Zuo-Tao; Maurer, Marcus
Title: Omalizumab in chronic inducible urticaria a real-life study of efficacy, safety, predictors of treatment outcome and time to response. Cord-id: ixie589u Document date: 2021_1_31
ID: ixie589u
Snippet: Chronic inducible urticaria (CIndU) is characterized by wheals, angioedema or both in response to specific and definite triggers[1] . Half of CIndU patients are refractory to H1 -antihistamine treatment even at higher doses[2] . Multiple studies have proven the benefits of omalizumab in chronic spontaneous urticaria[3] . Real life data on the efficacy and safety of omalizumab treatment in CIndU are limited[4, 5] .
Document: Chronic inducible urticaria (CIndU) is characterized by wheals, angioedema or both in response to specific and definite triggers[1] . Half of CIndU patients are refractory to H1 -antihistamine treatment even at higher doses[2] . Multiple studies have proven the benefits of omalizumab in chronic spontaneous urticaria[3] . Real life data on the efficacy and safety of omalizumab treatment in CIndU are limited[4, 5] .
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date